Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Clinical trial NCT02794571 · COMPLETED
Trial details
- NCT number
- NCT02794571
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-23
- Primary completion
- 2024-11-13
- Enrollment
- 518
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.